Drug intelligence / Profile preview

ABSGM003

Development stage: Preclinical
Lead developer: Agastiya Biotech
Modality: Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

ABSGM003 is a small molecule therapeutic candidate being developed by Agastiya Biotech for the treatment of diabetes. Currently in the preclinical stage of development, the specific molecular target and mechanism of action for ABSGM003 have not been publicly disclosed. The compound is part of Agastiya Biotech's internal research pipeline, which focuses on small molecule discovery for metabolic disorders and oncology.

Beyond the preview

Go deeper on ABSGM003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABSGM003.

Explore the full profile